Scarica l'app Stockscreener
4.84
3.59%
-0.18
Dopo l'orario di chiusura:
4.75
-0.09
-1.86%
Precedente Chiudi:
$5.02
Aprire:
$5.19
Volume 24 ore:
148.95K
Relative Volume:
2.23
Capitalizzazione di mercato:
$92.80M
Reddito:
-
Utile/perdita netta:
$-33.63M
Rapporto P/E:
-2.5309
EPS:
-1.9124
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
+1.68%
1M Prestazione:
+4.76%
6M Prestazione:
+27.37%
1 anno Prestazione:
+74.10%
Intervallo 1D:
$4.81
$5.20
Intervallo di 1 settimana:
$4.74
$5.20
Portata 52W:
$2.44
$5.20
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.84 | 96.25M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Iniziato | Roth Capital | Buy |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
PolyPid Q1 earnings call highlights - MSN
PolyPid (PYPD) Jumps 3.93% as Stock Approaches Key Resistance LevelSupport Level Bounce - Newser
PYPD Q1 2026 Earnings: EPS Beat on Operational Discipline, But Revenue Remains AbsentEarnings Season Review - Newser
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference - GlobeNewswire
PolyPid’s Earnings Call Signals Tightrope to Approval - TipRanks
PolyPid Ltd stock (US70450B1035): pivotal Phase 3 data and Nasdaq listing shift in focus - AD HOC NEWS
PolyPid Submits D-PLEX100 New Drug Application to FDA - HarianBasis.co
PolyPid Ltd.Ordinary Shares (NQ: PYPD - FinancialContent
PolyPid stock (US70450B1035): NDA submission advances D-PLEX100 toward FDA review - AD HOC NEWS
PolyPid Ltd. (NASDAQ:PYPD) Q1 2026 Earnings Call Transcript - Insider Monkey
PYPD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PolyPid Earnings Call: NDA Momentum Amid Cash Strain - TipRanks
PolyPid Q1 Earnings Call Highlights - sharewise.com
PolyPid Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
PolyPid Q1 2026 Earnings Call Transcript - MarketBeat
PYPD: NDA submission for D-PLEX100 nears completion as financials improve and commercialization advances - TradingView
PolyPid Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
PolyPid Q1 2026 Earnings Call: Complete Transcript - Benzinga
[6-K] PolyPid Ltd. Current Report (Foreign Issuer) | PYPD SEC FilingForm 6-K - Stock Titan
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results - marketscreener.com
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Rosalind Advisors/Fund report 9.9% in PolyPid (PYPD) via warrants and shares - Stock Titan
TradingKey - TradingKey
PolyPid Ltd expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Number of shareholders of PolyPid Ltd. – NASDAQ:PYPD - TradingView
How sustainable is PolyPid (PYPD) profit margins? (Smart Money Exits) 2026-05-08Street Ratings - newser.com
PolyPid (PYPD.US) will release its earnings report before the market opens on May 13. - Moomoo
PolyPid to Announce First Quarter 2026 Financial Results on May 13 and Host Conference Call at 8:30 AM ET - geneonline.com
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 - The Manila Times
Aurum holds 5,001,561 shares in Polypid Ltd. (PYPD) with exercisable warrants - Stock Titan
AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD - MarketBeat
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - BioSpace
PolyPid to present wound infection data at surgery conference By Investing.com - Investing.com South Africa
PolyPid to present wound infection data at surgery conference - Investing.com
PolyPid to Present Data from SHIELD II Phase 3 Trial - GlobeNewswire
PYPD Price Today: PolyPid Ltd. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Increases By 166.1% - MarketBeat
PYPD (PolyPid Ltd. Ordinary Shares) reports wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Tây Ninh
PolyPid (PYPD) Stock Outlook | Q4 2025: Earnings UnderperformHigh Growth - Cổng thông tin điện tử tỉnh Lào Cai
PolyPid Ltd stock (US70450B1035): Is its drug-delivery tech strong enough to unlock biotech upside? - AD HOC NEWS
PolyPid Ltd stock (US70450B1035): Is its drug delivery tech strong enough to unlock surgical market - AD HOC NEWS
Nir Dror Darwish Net Worth (2026) - GuruFocus
Itzhak Krinsky Net Worth (2026) - GuruFocus
PolyPid (PYPD) Stock Recovery Underway (-1.27%) 2026-04-16Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Yechezkel Barenholz Net Worth (2026) - GuruFocus
Dikla Czaczkes Akselbrad Net Worth (2026) - GuruFocus
Jonathan Missulawin Net Worth (2026) - GuruFocus
Yitzchak Shlomo Jacobovitz Net Worth (2026) - GuruFocus
PolyPid To Present Phase 3 SHIELD II Data Showing Sustained Local Doxycycline Release And Minimal Systemic Exposure At ESCMID 2026 Conference - Sahm
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):